Phase I, Phase I
A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2
Volunteers
Health Professionals
What is the purpose of this trial?
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Adriana Matutino Kahn, MD
- Carrie Fijal, MSN, AGPCNP-BC, OCN
- Jacquelyne Gaddy, MD, MSc, MSCR
- Jeremy Kortmansky, MD
- Joseph Kim, MD
- Katelyn Scott
- Kirsten Dooley
- Kristen Hoxie
- Laura Van Metre Baum, MD, MPH
- Mandy DeMerchant
- Pamela L. Kunz, MD
- Patricia LoRusso, DO
- Sara Anastasio, RN
- So Yeon Kim, MD
- Stacey Stein, MD
- Vanna Dest
- Virginia Syombathy
- Last Updated12/24/2024
- Study HIC#2000035924